AKT1 and posterior cortical atrophy: Though no drugs targeting this pathway have been approved in PCa, the AKT-inhibitor ipatasertib performed well in combination with abiraterone in a phase Ib/II study, and the IPATential150 phase III trial is underway [26,27].